ATRYS HEALTH, S.A. Inactive Instrument
Atrys Health, S.A. Share Price BME
Equities
ES0105148003
Healthcare Facilities & Services
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 22Cr 24Cr 1.99TCr | Sales 2025 * | 24Cr 26Cr 2.14TCr | Capitalization | 32Cr 34Cr 2.87TCr |
|---|---|---|---|---|---|
| Net income 2024 * | -20L -21.71L -18Cr | Net income 2025 * | 40L 43.42L 36Cr | EV / Sales 2024 * | 2.23 x |
| Net Debt 2024 * | 17Cr 19Cr 1.57TCr | Net Debt 2025 * | 16Cr 17Cr 1.45TCr | EV / Sales 2025 * | 2.02 x |
| P/E ratio 2024 * |
-127
x | P/E ratio 2025 * |
76
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.57% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 13/07/13 | |
| Director of Finance/CFO | - | 01/15/01 | |
| Corporate Secretary | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 01/16/01 | |
| Director/Board Member | - | - | |
Aurora Catá Sala
BRD | Director/Board Member | 60 | - |
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
| 1st Jan change | Capi. | |
|---|---|---|
| +20.09% | 8.46TCr | |
| -27.30% | 7.24TCr | |
| +2.04% | 2.77TCr | |
| -9.00% | 1.78TCr | |
| -1.14% | 1.71TCr | |
| +4.56% | 1.6TCr | |
| +69.72% | 1.31TCr | |
| +6.66% | 1.29TCr | |
| +73.30% | 1.25TCr |
